Stereotactic Body Radiotherapy & Liver Transplant for Liver Cancer
JAMA Network Open
doi.org/10.1001/jamane…
🔎phs-2🇭🇰, 32 pts
👉median size 5.1 cm, 53% solitary
👉ORR 87.5%, 15/20 pCR
👉mPFS 17.6, mOS 60.5 mo
🧐Supports SBRT as viable option for bridging to LTx
ESMO - Eur. Oncology

Botensilimab plus balstilimab in relapsed/ refractory MSS mCRC
nature
doi.org/10.1038/s41591…
🔎phs 1 trial, 148 heavily pre-treated pts
👉ORR 17%, DCR 61%
👉mPFS 3.5, mOS 20.9 mo
👉TRAEs 89%
👉No response in pts w/ liver mets
🔎New MOA -> promising

🔥FDA granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion🔥
👉more options for a rare genetic alteration
ESMO - Eur. Oncology

A new BRAF inhibitor breaks resistance barriers
Trends in Cancer
doi.org/10.1016/j.trec…
👉next generation BRAF inhibitor PF-07799933 with efficacy against mutations across all classes
👉no effect on WT BRAF/CRAF heterodimers
🧐🎯BRAF is getting more effective
ESMO - Eur. Oncology

Clinical significance of tumour-infiltrating lymphocytes & MSI status in CRC
The Lancet Gastroenterology & Hepatology
doi.org/10.1016/S2468-…
🔎Systematic review & network meta-analysis
👉better survival only in pts with TIL-H, regardless of MSI or MSS status
🧐helpful to guide therapy
ESMO - Eur. Oncology

🔥off the press: nal-IRI + 5-FU vs 5-Fu in cholangiocarcinoma previously treated with gemcitabine-based therapies
The Lancet Gastroenterology & Hepatology
🔎NALIRICC phs 2, 100 pts
👉Disappointing, no benefit w/ nal-IRI
🧐Meta-analysis with NIFTY will come..
👇my author link:
authors.elsevier.com/sd/article/S24…

Clinical impact of ctDNA to track minimal residual disease in CRC. Hopes and limitations
ESMO Open
doi.org/10.1016/j.esmo…
👏very comprehensive review
👉undeniable prognostic role, but still some work to do to intergrate as tool for optimal personalized treatment strategies

🔥news from #EASL2024
Liver transplantation following HCC downstaging with atezolizumab/bevacizumab: preliminary results of the ImmunoXXL study
👏still early, but amazing data
👉ICI before LTx seems feasible & safe
🧐Real chance to improve outcome in HCC
EASL Education ESMO - Eur. Oncology

🔥news from #EASL2024
Outcome of pts with HCC who achieved a complete response to ICI-based therapy
👉🗺️RWD, 174/3933 pts
👉mRFS 30 mo, 3yr OS 87%
😅Great to report recurrence free survival (!) after systemic therapy in advanced HCC
ESMO - Eur. Oncology EASL Education ILCA #livertwitter

Upfront resection vs no resection of the primary tumor in metastatic colorectal cancer
Annals of Oncology
doi.org/10.1016/j.anno…
🔎Phs 3 CAIRO4, 206 pts
👉mOS 18.3 vs 20.1 mo
👉AEs ≥3° 72% vs 65%
🧐Upfront PTR to palliative systemic therapy does not improve survival
ESMO - Eur. Oncology

EASL Clinical Practice Guidelines on genetic cholestatic
liver diseases
Journal of Hepatology
doi.org/10.1016/j.jhep…
😅extremely helpful summary on cholestatic liver disease
EASL Education ILCA #livertwitter

EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
Journal of Hepatology
doi.org/10.1016/j.jhep…
👏Important update & summary on steatotic liver diseases
EASL Education ILCA #livertwitter

Nanoliposomal Irinotecan With 5-Fu or Gemcitabine + Cisplatin in Advanced Cholangiocarcinoma
🔎NIFE-AIO-YMO HEP-0315
Journal of Clinical Oncology
doi.org/10.1200/JCO.23…
👉mPFS 6 vs 6.9 mo
👉mOS 15.9 vs 13.6 mo
🧐There is efficacy of irinotecan, but.. 1st line, 2nd line?
ESMO - Eur. Oncology ILCA EASL Education

Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
doi.org/10.1158/2159-8…
👉non-covalent inhibitor of the active, GTP-bound (ON) state of mutant & WT RAS
👉tolerable & durable pan-tumor responses
🧐 RAS is getting druggable…
ESMO - Eur. Oncology

Nivolumab + ipilimumab in HCC previously treated with sorafenib
Annals of Oncology
doi.org/10.1016/j.anno…
🔎5-yrs update CheckMate 040
👉ORR 34 vs 27 vs 29%
👉DOR 51.2 vs 12.6 vs 15.2 mo
👉mOS 22.2 vs 12.5 vs 12.7 mo
😅Timely update, CM 9DW just published #ASCO24
ESMO - Eur. Oncology